文献速递基础与转化研究临床试验与 GCP

慢病毒或γ逆转录病毒基因修饰T细胞疗法的长期安全性

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
PubMed 文献 · Nat Med · 2025-01-20

本研究评估了38项T细胞疗法试验中783例患者、累计超过2200患者年的安全性结局。18例(2.3%)发生继发恶性肿瘤,中位发病时间1.94年(范围51天至14年);可分析样本未见高水平载体标记或插入性突变证据,1例T细胞淋巴瘤的恶性T细胞无载体整合。176例载体整合位点分析未发现与继发恶性肿瘤相关的病理性插入,但部分病例肿瘤抑制基因附近整合与适度克隆扩增和持续T细胞存留相关。

要点

  • 783例患者中18例(2.3%)发生继发恶性肿瘤,中位发病时间1.94年。
  • 可分析肿瘤样本未见高水平载体标记或插入性突变证据。
  • 1例T细胞淋巴瘤的恶性T细胞无载体整合。

核心结论

  • 工程化T细胞疗法在长期随访中表现出安全性,继发恶性肿瘤发生率低且未发现插入性突变证据。

研究设计与样本

  • 来自38项T细胞疗法试验的783例患者,累计超过2200患者年观察,采用整合型γ逆转录病毒或慢病毒载体递送工程受体以靶向HIV-1感染或癌症。

主要发现

  • 18例患者(2.3%)治疗后发生继发恶性肿瘤,中位发病时间1.94年(范围51天至14年)。
  • 可分析的肿瘤样本未显示高水平载体标记或其他插入性突变迹象。
  • 检测到1例T细胞淋巴瘤,但恶性T细胞无载体整合标记。
  • 176例患者的载体整合位点分析未发现与继发恶性肿瘤相关的病理性插入。
  • 部分病例中肿瘤抑制基因等特定基因内或附近整合与适度克隆扩增和持续T细胞存留相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long-term risks of gene therapy are not fully understood. In this study, we evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T cell therapy trials. The trials employed integrating gammaretroviral or lentiviral vectors to deliver engineered receptors to target HIV-1 infection or cancer. Eighteen patients (2.3%) developed secondary malignancies after treatment, with a median onset of 1.94 years (range: 51 d to 14 years). Where possible, incident tumor samples were analyzed for vector copy number, revealing no evidence of high-level marking or other indications of insertional mutagenesis. One T cell lymphoma was detected, but malignant T cells were not marked by vector integration. Analysis of vector integration sites in 176 patients revealed no pathological insertions linked to secondary malignancies, although, in some cases, integration in or near specific genes, including tumor suppressor genes, was associated with modest clonal expansion and sustained T cell persistence. These findings highlight the safety of engineered T cell therapies.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Jadlowsky JK, Hexner EO, Marshall A, et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med. 2025. PMID: 39833408. doi:10.1038/s41591-024-03478-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。